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Proposed changes to management of lower respiratory tract infections
in response to the Clostridium difficile epidemic
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Clostridium difficile infection (CDI) remains a major healthcare problem associated with antibiotic use in hospi-
tals. Recent years have seen a dramatic increase in the incidence of CDI in the UK and internationally. Lower
respiratory tract infections (LRTIs) are the leading indication for antibiotic prescription in hospitals and are
therefore a critical battleground in the fight against inappropriate antibiotic use and healthcare-associated
infections. This article reviews the evidence for interventions to reduce CDI in hospitalized patients with
LRTIs. Reducing prescriptions of cephalosporins and fluoroquinolones in favour of penicillin-based regimens
and increased use of tetracyclines have been proposed. Expanding outpatient management of LRTIs and
reducing length of hospital stay will limit patient exposure to the healthcare environment in which C. difficile
is most easily acquired. Intravenous (iv) broad-spectrum antibiotics are often prescribed when narrower
spectrum, oral antimicrobials would be equally effective and, in a proportion of patients, antibiotic therapy is
used unnecessarily. Shorter antibiotic regimes may be as effective as prolonged therapy and reduce anti-
biotic-related complications. Early switch from iv to oral therapy allows simpler antibiotic regimens and
facilitates early discharge from hospital. Simple improvements in the management of LRTIs have the potential
to reduce the incidence of healthcare-associated infections.
Keywords: pneumonia, antibiotics, severity assessment, resistance, guidelines
Introduction
The 2009 update of the British Thoracic Society (BTS)
community-acquired pneumonia (CAP) guidelines has recently
been published.1 Publication takes place against a backdrop of an
unprecedented epidemic of hospital-acquired infections.2 The
increasing incidence of methicillin-resistant Staphylococcus aureus
(MRSA) and Clostridium difficile infections (CDIs) has attracted the
concern of physicians, politicians, journalists and the public.2
The inappropriate, excessive or unnecessary use of antibiotic
therapy is among the leading causes of the spread of resistant,
hospital-acquired organisms.3 If we are to target inappropriate
usage of antibiotics, focusing on their usage in respiratory tract
infections (RTIs) is a logical starting point as they are the most
common infectious diseases requiring hospitalization in
Western countries.4,5 Many countries have seen an increase in
broad-spectrum antibiotic use in CAP,6 including the UK.7 Broad-
spectrum antibiotics are strongly associated with CDI, and as
such the C. difficile epidemic cannot be addressed without
addressing antibiotic prescribing for RTIs.
In this review we discuss the role of antibiotic prescribing and
management practices in RTIs that may have contributed to the
rise of C. difficile, and discuss proposed changes to management
that aim to control the epidemic.
Literature sources
The current review was based on a search of PubMed for articles
using major MeSH terms ‘Clostridium difficile’, ‘pneumonia’ and
‘respiratory tract infection’ between 1970 and September 2009.
Separate searches of PubMed were performed using the above
search terms in combination with text terms ‘cephalosporins’,
‘macrolides’, ‘co-amoxiclav’, ‘penicillin’, ‘tetracyclines’, ‘severity’,
‘biomarkers’ and ‘intravenous antibiotics’. The literature search
was supplemented by reviewing relevant national guidelines,
reference lists and the authors’ personal files.
The extent of the problem
C. difficile is a Gram-positive, anaerobic, spore-forming bacillus
that infects the large bowel.2 CDI is most frequently acquired
within healthcare facilities, although community-acquired infec-
tion is increasingly recognized.8 It is strongly associated with the
use of broad-spectrum antibiotic therapy.9 Manifestations range
from trivial diarrhoea to life-threatening pseudo-membranous
colitis.10
It has been estimated that an average district general hospi-
tal in the UK will incur costs of £400000 and .200 additional
bed days annually due to CDI.11 Cases of CDI have risen
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dramatically over the last 20 years.2,12 Recent UK Department of
Health statistics reported 10846 cases of CDI in the National
Health Service (NHS) from April to June 2008, with 80% of
these cases reported in patients over the age of 65 years. Over
50000 cases of CDI were reported in England in 2007 and CDI
was cited in .4000 death certificates.2 This contrasts with
,5000 cases in England in 1993 when the first BTS CAP guide-
lines were introduced, and 20000 cases in the year 2000. In
our own hospitals in Tayside, UK, ICD-10 (International Statistical
Classification of Diseases and Related Health Problems 10th Revi-
sion) discharges citing C. difficile have risen dramatically since
1998 (Figure 1). This pattern is similar to that reported by
many UK NHS institutions.2 Although these trends may be
partly explained by increased awareness and increased testing
for the disease, it is widely accepted that the incidence is
rising. CDI in UK hospitals has been described as an epidemic.
When discussing the causes of these increases, hospital clean-
ing receives much of the media attention and is a key part of the
overall strategy to reduce hospital-acquired CDI.13 Hand washing
is critical to preventing the spread of infection within hospitals
once it is established, and there is evidence of poor hand washing
practice among medical, nursing and support staff that may
have contributed to the spread of CDI.14,15 Good infection control
procedures are essential, including isolation of cases and barrier
nursing.16,17 An increasingly virulent C. difficile strain, known as
ribotype 027, has been described.18 This novel strain produces
increased quantities of C. difficile toxins A and B along with an
additional binary toxin. Disease associated with this strain is
reported to be more severe and more difficult to treat. Other
medical factors such as increasing prescriptions for gastric acid
suppressant drugs have played a role.19 There is, however, broad
agreement that antibiotic therapy is one of the primary drivers of
CDI in hospitals.20 Respiratory infections are the leading indication
forantibiotic prescribing in UK hospitals, and therefore potentially a
majordriverofCDIandotherhealthcare-associated infections.21,22
How does CAP management contribute to CDI?
In the UK, 80% of antibiotic prescribing takes place in primary
care, and 80% of these prescriptions are for lower RTI (LRTI).21
The majority of these prescriptions broadly follow the national
recommendations for treatment of CAP although chest radio-
graph confirmation is not sought in most cases and many will
represent cases of viral infections or upper RTIs. In the secondary
care environment, CAP is the most common cause of severe
sepsis and accounts for 6% of all intensive care unit (ICU) admis-
sions in the UK.23 Hospital admissions for infectious disease and
particularly CAP have been rising in recent years and the average
age of the UK population is also rising.7 This has the effect of
increasing antibiotic prescribing in hospitals, particularly to
elderly patients, thereby significantly increasing the number of
patients at risk of developing CDI.
Regrettably, there are no studies, in the UK or internationally,
that specifically address the issue of CDI as a complication of
CAP therapy. Most studies have examined antibiotic use in hospi-
tals without considering the diagnosis for which they were pre-
scribed. It is notable, however, that of the four classes of
antibiotic most strongly implicated in the CDI epidemic (second-
and third-generation cephalosporins, ‘respiratory quinolones’,
macrolides and clindamycin) all except clindamycin are, or have
been, most frequently prescribed for respiratory infections.
Antibiotics save lives in CAP.24 Prior to the widespread intro-
duction of antibiotics in the 1950s, patient mortality in CAP
was .50%; however, this figure has now fallen to 10%.
There are currently no therapies other than antibiotics that
have been proven to reduce mortality in CAP and no new thera-
pies have been licensed for CAP since antibiotics were introduced.
Despite the efficacy of antibiotics in CAP, the number of deaths
attributable to CAP greatly exceeds those attributable to CDI.
For example, in Scotland, C. difficile was recorded on 2088
death certificates between 2001 and 2007, whereas pneumonia
was directly responsible for 17534 deaths over the same
period.25 The mortality rate for hospitalized patients with CAP
is 5.7%–14% based on UK studies,1 while in the UK CDI has
been associated with a 28 day mortality of 11%–23%.26
Some of the ways in which management practices in LRTIs
may contribute to CDI are summarized in Figure 2. It should be
emphasized that while this review has focused on C. difficile,
these practices may also contribute to other healthcare-
associated and antibiotic-resistant infections such as MRSA and
extended-spectrum b-lactamase-producing Escherichia coli.
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Figure 1. ICD-10 discharges reporting C. difficile as a diagnosis in NHS
Tayside 1998–2008.
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Figure 2. Management practices in CAP that may contribute to
increasing CDI.
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The role of national guidelines
The first BTS guidelines for the management of CAP in adults
were published in 1993.27 In the absence of a robust evidence
base on the aetiology or management of CAP in the UK at that
time, consensus guidelines, based largely on expert opinion,
were produced. The guidelines were widely criticized: second-
and third-generation cephalosporins were recommended for
severe CAP; the severity scoring system classified the majority
of elderly patients in the severe category, regardless of physio-
logical embarrassment; and the guidelines did not clearly differ-
entiate between CAP and non-pneumonic respiratory illness.
These factors were accused of contributing to the CDI epidemic,
owing to excessive use of high-risk antibiotics, to at-risk patients,
with little indication.28–33
After the publication of the first BTS guidelines in 1993, anti-
biotic consumption data, along with reports from various hospi-
tals, demonstrated a progressive increase in the use of
cephalosporins and macrolide antibiotics.28,30–33 At this time
the extent of the C. difficile epidemic became clear; many hospi-
tal Trusts rejected the BTS recommendations. In the 1999 BTS
survey, nearly 20% of respiratory units reported concern over
CDI, and although 65% reported the use of the combination of
cephalosporin and macrolide antibiotics for severe CAP, as
suggested by the guidelines, other regimens such as co-
amoxiclav and benzylpenicillin-based regimens were also
reported.34 The survey demonstrated, however, that there was
significant misunderstanding of the guidelines, with nearly a
quarter of respondents recommending b-lactam/macrolide
dual therapy for non-severe CAP and some even recommending
cephalosporins for mild CAP.
Misinterpretation of the guidelines, rather than the guideline
recommendations themselves, may have influenced much of
the subsequent problem. Nevertheless, significant changes
were made when the guidelines were reviewed in 2001.31 By
2009, CDI rates in England had increased by 400%.2
Risk factors for CDI in CAP patients
The antibiotics most strongly associated with the development
of C. difficile diarrhoea include clindamycin and third-generation
cephalosporins.2,8,9,11 More recently fluoroquinolones, carbape-
nems and prolonged courses of aminopenicillins have been
implicated.2,35,36
CDI disproportionately affects elderly patients, and up to 90%
of patients presenting to hospital with CAP are over the age of
65 years.37 Many have other risk factors for development of
CDI (Table 1).
Cephalosporins
The antimicrobial spectrum of cephalosporin antibiotics is wide;
in addition to coverage of Streptococcus pneumoniae, cephalos-
porins provide coverage of methicillin-susceptible S. aureus and a
spectrum of Gram-negative organisms.
Since the 1993 BTS CAP guidelines, cephalosporins have been
the most frequently used antibiotics for patients with severe CAP
in the UK.34 The administration of second- and third-generation
cephalosporins, particularly to elderly patients, is strongly associ-
ated with the development of C. difficile diarrhoea.28 This
association was recognized as early as the 1970s, but the
scale of the problem was not recognized until the mid-
1990s.20 Since then, efforts have been made to reduce
cephalosporin prescribing.
There is evidence of reduction in CDI following restriction of
use of cephalosporins and clindamycin. These interventions
result in significant immediate reductions in the incidence of
CDI, but a less impressive long-term reduction. A recent sys-
tematic review pooled the results of these antibiotic restriction
interventions and reported an immediate reduction of 90
cases of CDI per year, but with a sustained decrease of only 12
cases per year.36 Many of these studies report interventions in
the context of outbreaks. The natural history following an out-
break is for there to be a decline in cases over time, a concept
known as regression to the mean, and as such the significance
of the intervention is not straightforward to interpret. Another
systematic review has described the majority of these studies
as poor quality and having major methodological limitations.46
Fluoroquinolones
Two ‘respiratory quinolones’ are licensed for use in the UK; moxi-
floxacin and levofloxacin. Neither is recommended as a first-line
agent, but they have been considered as second-line alternatives
since the 2001 BTS guidelines.31 These agents are active against
all the major bacterial pathogens causing CAP including
S. pneumoniae, Legionella pneumophila and other ‘atypical’
organisms. Resistance to fluoroquinolones is extremely low in
the UK; ,1% of pneumococcal isolates are resistant to levoflox-
acin.47 Their broad spectrum of action makes fluoroquinolones
an attractive option for CAP. There is, however, minimal evidence
that they are more effective than narrower spectrum agents.
A recent meta-analysis, focusing primarily on fluoroquinolones,
showed no survival benefit when comparing regimens covering
atypical pathogens with narrower spectrum regimens.48
Fluoroquinolone use was encouraged in the 2001 BTS guide-
lines as these agents were, at that time, associated with a low
risk of CDI. Reports, however, suggest fluoroquinolones are emer-
ging as a major cause of CDI, and are particularly associated
with the epidemic and hypervirulent 027 ribotype.18,35 Fluoroqui-
nolones, particularly moxifloxacin, have been shown to induce C.
difficile growth and toxin production in an animal model of
Table 1. Risk factors for development of CDI
CDI risk factor
Age .65 years38
Co-morbidities
Severity of presenting illness9,39
Admission from nursing home
Malignancy (particularly haematological malignancy)40,41
Prolonged hospitalization39,42
Gastric acid suppressant medications19,42,43
Immunosuppression42
Intensive care unit admission
Nasogastric intubation44
Inflammatory bowel disease44
Gastrointestinal and transplant surgery
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CDI.49 A study following an outbreak in Quebec, Canada, found
fluoroquinolones were the antibiotic most strongly associated
with CDI; adjusted hazard ratio (AHR) of 3.44 [95% confidence
interval (CI) 2.65–4.47]. In contrast, cephalosporins carried less
than half the risk [the AHR in this study was 1.56 (95% CI 1.15–
2.39)].39
Macrolides
Macrolides are reported to reduce mortality in severe pneumo-
nia. This evidence is based almost entirely on observational,
uncontrolled studies with a large potential for bias by indication.
There is, nevertheless, a large body of such evidence from differ-
ent populations and different healthcare systems.50–60 BTS
guidelines recommend the use of macrolide antibiotics for mod-
erate and severe pneumonia only; however, there is widespread
use of macrolide antibiotics in mild pneumonia despite this.
Macrolides, such as clarithromycin, have some activity against
enteric anaerobes and so promote the overgrowth of C. difficile.61
Determining the impact of macrolide therapy on CDI in clinical
practice is difficult because guideline-based practice is to use
macrolide antibiotics in combination with cephalosporins or ami-
nopenicillin/b-lactamase inhibitor combinations, not as mono-
therapy. The study by Impallomeni et al.28 found an odds ratio
(OR) for the development of CDI of 2.8 for erythromycin
therapy, whereas MacGowan et al.62 found an association
between macrolide use in the 7 days prior to onset of CDI.
There are no studies reporting the effect of restriction of macro-
lide therapy on CDI or other hospital-acquired infections.
Aminopenicillin/b-lactamase inhibitors (co-amoxiclav)
Since 2001 the BTS guidelines have recommended co-amoxiclav
as first-line therapy for severe CAP.31 Co-amoxiclav has a
broad spectrum of antimicrobial activity, notably against
S. pneumoniae, Haemophilus influenzae and S. aureus, in addition
to possessing some anaerobic activity. It is this activity against
enteric anaerobic bacteria that makes it an agent likely to
induce C. difficile; indeed co-amoxiclav treatment can promote
C. difficile proliferation in healthy volunteers.63 Co-amoxiclav
was the second most likely class of antibiotic to induce CDI in
the early meta-analysis by Bignardi (OR 22.1, 95% CI 6.5–
75.4).9 This study took place before the use of fluoroquinolones
increased and the epidemic 027 strain was described.
Depending on local strain epidemiology, co-amoxiclav may be
less likely to induce CDI compared with cephalosporins or fluoro-
quinolones. Nevertheless, a number of UK hospitals have
encountered problems with co-amoxiclav predisposing to CDI
and this, in part, explains the increasing use of benzylpenicillin-
based regimens as first-line therapy for severe CAP.64
Fowler et al.65 reported a reduction in CDI rates in a time-
series analysis in which co-amoxiclav and cephalosporin pre-
scribing were restricted in favour of antibiotics less associated
with CDI. The study, however, did not report pneumonia-specific
mortality and used a combination treatment of benzylpenicillin
and trimethoprim, which is not a well-recognized therapy
option in CAP treatment.
Narrow-spectrum penicillins and tetracyclines
Narrow-spectrum penicillins and tetracyclines are widely
regarded as the lowest risk agents for inducing CDI. Oral penicillin
monotherapy has been used in Scandinavian countries for many
years for mild pneumonia. The Scandinavian countries have a
long-standing history of restrained antibiotic use and conse-
quently have low rates of antimicrobial resistance and a low fre-
quency of hospital-acquired infections.66 Cephalosporins are the
most widely recommended agents worldwide, even in Scandina-
vian countries.67
Tetracyclines are recommended by the 2009 BTS guidelines as
an alternative therapy for mild pneumonia in penicillin-allergic
patients.1 Previous recommendations to use macrolides as
alternative therapy have been questioned in light of increasing
macrolide resistance among S. pneumoniae. UK pneumococcal
resistance to erythromycin has increased to 14.6% of blood
culture isolates and 12% of respiratory isolates. Comparatively,
tetracycline resistance is 4% and 7.6%, respectively.68 Doxycy-
cline is licensed for use in the UK for treatment of mild CAP. Its
spectrum of action covers the majority of respiratory bacterial
pathogens including Mycoplasma pneumoniae, Chlamydophila
pneumoniae and L. pneumophila in addition to S. pneumoniae.
Although the evidence base for doxycycline in pneumonia is
weak, with an absence of randomized controlled trials, it has
been used in Scandinavian countries for many years with
success. Tetracyclines may represent an important part of the
strategy to reduce CDI. A previous systematic review has
shown that compared with third-generation cephalosporins (OR
36.2, 95% CI 19.0–68.9) and fluoroquinolones (OR 8, 95% CI
4.5–14.3), tetracyclines were the least likely antibiotics to
cause CDI (OR 1.3, 95% CI 0.1–19.6).9
In summary, reduced use of cephalosporins and fluoroquino-
lones, judicious use of macrolides and increased use of penicillin-
based regimens and tetracyclines for mild CAP is likely to result in
a reduced incidence of CDI.
Severity assessment tools and antibiotic
prescribing
In the UK, initial antibiotic prescribing is often done by junior
doctors. Studies have found that junior doctors in the UK have
poor knowledge of the UK CAP guidelines.69,70
Severity assessment tools have been derived to guide initial
management of patients with CAP.71,72 These are based on the
risk of 30 day mortality, but have been recommended to guide
antibiotic choice in the BTS guidelines.1,72 These provide objective
means of choosing which patients require broad-spectrum anti-
biotic therapy and, in theory, may therefore reduce unnecessary
treatment. They may be particularly useful for doctors with less
experience of managing CAP. Many scoring systems have been
derived, but the most widely used in the UK is the CURB65
score, the components of which are shown in Figure 3.1,72 This
score has been independently validated in .13000 patients in
10 countries.72–79 The BTS recommends outpatient treatment
for patients in the lowest risk CURB65 classes (0 and 1).
Severity scores have been successfully used to increase the
number of patients treated on an outpatient basis.80 This strat-
egy has obvious advantages in terms of reducing potential
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exposure to C. difficile. It is notable, however, that a large pro-
portion of patients at low risk of death require admission to hos-
pital.81 This is particularly true in the elderly where admission
may be required for social reasons and significant co-morbidity
rather than the severity of pneumonia.82 Studies relating to the
impact of CURB65 in clinical practice are limited. At the time of
writing no studies have reported CURB65-guided therapy being
used to successfully increase the proportion of patients treated
at home. Use of severity assessment tools to guide antibiotic
therapy has not been studied, although the theoretical basis
(that patients at low risk of death require narrower spectrum,
oral antibiotic therapy) is sound.
In the future, biomarkersmay be used to predict severity and to
guide antibiotic therapy. The traditional biomarker, C-reactive
protein (CRP), is widely available and correlates to some extent
with severity of pneumonia.83 It is not, however, sufficiently sensi-
tive or specific to determine the requirement for antibiotic
therapy.84 Procalcitonin is a precursor of the hormone calcitonin
and is raised substantially in bacterial infections. Procalcitonin
has emerged as a potentially useful guide to antibiotic prescription
in respiratory infections. In a randomized study in hospitalized
patients with acute RTI, an admission procalcitoninmeasurement
wasused todeterminewhetherpatients should receiveantibiotics.
One arm of the study received procalcitonin-guided antibiotic
therapy while the other received standard therapy. At the con-
clusion of the trial, there were 50% fewer antibiotic prescriptions
in the procalcitonin group, with nomajor impact on outcome.85,86
The largest trial to date of procalcitonin-guided antibiotic
therapy has recently been published.87 This multicentre trial of
1359 patients with LRTIs found that procalcitonin guidance was
associatedwith amean reduction of 3 days in duration of antibiotic
therapy with no increase in mortality or clinical failure. This
reduction was associated with a significant reduction in
antibiotic-related side effects.87 Unfortunately, procalcitonin
assays are currently not widely available in the UK and comparison
with other severity indices, biomarkers (including CRP) and
independent validation of these findings is required before we can
consider using biomarkers to limit antibiotic use in respiratory
infections.
In summary, validated severity markers have the potential
to reduce inappropriate antibiotic use and to encourage out-
patientmanagement of CAP, with the likely result of reducing CDI.
Duration of antibiotic therapy
National guidelines recommend 7 days of antibiotic therapy for
mild CAP, with 7–10 days therapy recommended for severe
pneumonia.1 Evidence from the UK is lacking, but an inter-
national audit recently showed variation in antibiotic duration
from 3 to 28 days, variation that is not accounted for by the
severity of pneumonia or patient response to treatment.88
Prolonged antibiotic therapy is associated with CDI and there-
fore shorter courses of antibiotic therapy may have a role in
reducing C. difficile as well as other resistant organisms.2,89 Evi-
dence suggests that short-course regimens (7 days) are at
least as effective as longer courses. For mild to moderate
pneumonia, even shorter durations may be possible. In one
study in the Netherlands, patients were randomized after 72 h
of intravenous (iv) amoxicillin treatment either to a further 5
days of oral amoxicillin or to placebo. After 10 and 28 days of
follow-up, there were no significant differences in clinical
success between the group receiving 3 days of treatment and
the group receiving 8 days of treatment.90
A recent meta-analysis of randomized controlled trials com-
paring short-course treatment (7 days) and longer treatment
(.7 days) showed no significant differences in terms of clinical
efficacy, bacterial eradication or mortality.91
Limiting the duration of antibiotic therapy to the minimum
necessary to achieve clinical success is likely to reduce adverse
effects and may be associated with a reduced incidence of
C. difficile.
Oral amoxicillin
Outpatient management
Low risk
0 or 1 point
Intermediate risk
2 points
New onset mental confusion
Urea >7 mmol/L
Respiratory rate ≥30/min
Systolic blood pressure <90 mmHg and/or diastolic blood pressure ≤60 mmHg
Age ≥65 years
CURB65 score
High risk
3-5 points
Inpatient management Inpatient management
Oral amoxicillin and
macrolide
Intravenous co-amoxiclav and macrolide
Figure 3. BTS-recommended therapy for CAP. Adapted by permission from BMJ Publishing Group Limited from Lim et al.1
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Switching iv antibiotics to oral therapy
Many patients with CAP require initial treatment with iv anti-
biotics, due to severity, impaired swallowing or concerns about
gastrointestinal absorption of drugs. Many patients, however,
are treated with iv antibiotics where oral therapy would be ade-
quate. In one audit in Dundee, 85%–90% of patients receiving iv
antibiotics in hospital could have been managed with oral medi-
cation.92 Oral therapy has several advantages, but in the context
of CDI the main advantage is that it may facilitate early dis-
charge from hospital, and therefore from the environment in
which CDI is most easily acquired.
The UK Department of Health guidance has suggested a 48 h
iv/5 day oral antibiotic approach with automatic stop dates.2
While this may be inappropriate for some cases of high-severity
pneumonia, in principle this has many advantages. Early iv to
oral switch may shorten length of stay in uncomplicated pneu-
monia and may also facilitate simplification of regimens, and
reduce use of cephalosporins (because, in the UK, iv cephalospor-
ins are usually switched to oral aminopenicillins).
In an open-label, controlled trial in the Netherlands,
Oosterheert et al.93 randomized 302 patients with severe pneu-
monia to either 7 days of iv antibiotics or 3 days of iv antibiotics
followed by automatic switch to oral antibiotics at day 3 if clini-
cally stable. After 28 days of follow-up the group with early iv to
oral switch had an equivalent mortality rate (4% versus 6%) and
a similar rate of clinical cure (83% versus 85%).93
Table 2. Clinical parameters suggesting safety of iv to oral switch in CAP
BTS recommendations1 Clinical stability (Halms) criteria94
† resolution of fever for .24 h
† pulse rate ,100 beats/min
† resolution of tachypnoea
† clinically hydrated and taking oral fluids
† resolution of hypotension
† absence of hypoxia
† improving white cell count
† non-bacteraemic infection
† no microbiological evidence of Legionella, staphylococcal
or Gram-negative enteric bacilli infection
† no concerns over gastrointestinal absorption
† temperature 37.88C
† respiratory rate 24 breaths/min
† systolic blood pressure 90 mmHg
† arterial oxygen saturation 90%
† ability to maintain oral intake
† normal mental status
Restricted use of
cephalosporins and
ﬂuoroquinolones
Simplify therapy
on the basis of
microbiology
results
Antibiotic therapy guided
by validated severity
assessment tool
Limit duration of
treatment and stop
unnecessary
antibiotics
Antibiotic policies
clearly differentiating
CAP from other LRTIs
(exacerbations of 
chronic  obstructive
pulmonary disease
and acute bronchitis)
Early iv to oral
switch
Decreased
Clostridium
difficile
infection
Reduce hospital
admissions and
length of stay
using validated
criteria
Increase use of
simple antibiotics
e.g. penicillins
and tetracylines
in mild CAP
Figure 4. Management practices in CAP that may contribute to reducing CDI.
Review
613
JAC
 at Edinburgh U
niversity on June 19, 2013
http://jac.oxfordjournals.org/
D
ow
nloaded from
 
The BTS guidelines emphasize the importance of clinical
judgement in making the decision to switch to oral antibiotics
and note that there is a limited amount of evidence to guide
when to make the iv to oral switch. In general, they rec-
ommend that in a patient who is clinically improving and is
afebrile for 24 h, switching to oral therapy should be
considered.
Studies have described clinical stability criteria that provide an
objective means of classifying whether a patient has responded
appropriately to therapy, and therefore an objective means of
identifying patients who may be switched from iv to oral medi-
cation, or discharged from hospital (Table 2).1,94 Evidence
suggests that once patients reach clinical stability, switching to
oral therapy and hospital discharge are safe and associated
with a very low rate of relapse.94,95 Audits suggest that up to
20% of patients are kept on iv therapy inappropriately in hospi-
tals.21 Patients may also be kept in hospital for longer than is
necessary, with resultant increased exposure to hospital-
acquired infections. Data from the UK are lacking, but data
from the USA, in the landmark PORT study, found that 22% of
patients were kept in hospital after they were clinically stable.
Reasons included unavoidable delays (treatment of
co-morbidities, delays in organizing long-term care), but also
areas where discharge could be expedited (such as the belief
that patients should remain in hospital to complete antibiotic
courses).96
Table 3. Summary of evidence supporting changes to management of LRTIs
Recommendation
Evidence for reduction of C. difficile/hospital-acquired
infection Evidence of benefit/safety in CAP
Restricted use of:
cephalosporins meta-analysis suggests sustained reduction in CDI
following restriction of cephalosporins36
there is no evidence that cephalosporins are superior to
the alternative agents in the treatment of CAP
fluoroquinolones strong association with epidemic 027 ribotype;35 limited
evidence on the effect of fluoroquinolone restriction
meta-analysis suggests no benefit of using
fluoroquinolones compared with alternative agents48
co-amoxiclav one study suggests reduced risk of CDI following
co-amoxiclav restriction alongside cephalosporin
restriction65
there is no evidence to suggest that co-amoxiclav is
superior to other agents in the treatment of CAP
Treatment of mild LRTIs with:
tetracyclines identified as agents least likely to cause CDI in one
meta-analysis9
limited evidence, but used successfully for many years
in Scandinavian countries;66 low rates of
S. pneumoniae resistance in the UK68
oral penicillin limited evidence; widely used in Scandinavian countries
where rates of CDI and antibiotic resistance are low67
limited evidence, but used successfully for many years
in Scandinavian countries;67 low rates of
S. pneumoniae resistance in the UK68
Severity-guided antibiotic
therapy using validated
severity tools
no evidence specifically related to CDI or
antibiotic-resistant organisms
severity tools have been widely validated72–79 and are
recommended by national and international
guidelines1
Increased outpatient
management of mild LRTIs
C. difficile is predominantly hospital acquired;2 although
no trials exist, outpatient management is likely to be
associated with reduced risk of acquiring CDI
outpatient management for mild CAP is equivalent to
inpatient management in terms of mortality,
complications and patient satisfaction with care80
Early discharge in clinically
stable patients
C. difficile is predominantly hospital acquired;2 although
no trials exist, outpatient management is likely to be
associated with reduced risk of acquiring CDI
length of hospital stay has been reduced in a number
of clinical studies without compromising patient
safety83,93,95,101
Early iv to oral switch therapy no specific studies in reducing C. difficile, but will
contribute to reducing broad-spectrum antibiotic use
and length of hospital stay
a randomized controlled trial found early iv to oral
switch in patients with severe pneumonia equivalent
to 7 days iv therapy in terms of mortality and
treatment success93
Shorter antibiotic courses duration of antibiotic therapy is linked to CDI2,89 a meta-analysis of randomized controlled trials suggest
that short versus longer course antibiotic regimes in
mild–moderate CAP are at least as effective in terms
of mortality and overall clinical efficacy91
Reduced inappropriate
prescribing
measures to reduce inappropriate prescribing and
reduce antibiotic use (particularly cephalosporins and
clindamycin) are associated with reduced CDI36
none of the studies on restrictive antibiotic policies has
reported increased mortality from infectious disease
as a consequence
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Early iv to oral switch and early hospital discharge are likely to
reduceCDI rates, inaddition to improvingcost-effectivenessof care.
Reducing inappropriate antibiotic use in RTIs
It has been suggested that up to 50% of antibiotic use in hospi-
tals is inappropriate.36 Inappropriate antibiotic therapy is a broad
term, but in the context of RTIs refers to the use of regimens that
are unnecessary (e.g. antibiotic treatment in viral infections or
upper RTI), excessive (such as cephalosporin use in mild CAP),
inadequate for the likely organisms (e.g. ciprofloxacin, which
has poor activity against S. pneumoniae) or insufficient (such
as failure to cover atypical organisms or S. aureus in patients
admitted to the ICU).
Changes in junior doctor practices and the expansion of the
new speciality of acute medicine in the UK mean that a large
proportion of CAP patients are now not managed initially by res-
piratory physicians.1 Most studies suggest that concordance with
national guidelines is low.69,70
Diagnosis of CAP is also suboptimal. One study found 29% of
patients diagnosed with CAP in hospital had a normal chest
X-ray.97 In another UK study, 50% of patients enrolled in the
‘CAP’ cohort had a normal chest X-ray.98 Although some of
these patients with LRTI may require antibiotic therapy [e.g.
infective exacerbations of chronic obstructive pulmonary
disease (COPD)] there is evidence that patients without pneumo-
nia are treated with cephalosporins and combination therapy.
This is particularly the case for COPD where overtreatment with
antibiotics is common.99
Despite clear guidelines from the BTS, inappropriate antibiotic
therapy still appears widespread. The BTS recently re-audited
local practices for the management of CAP as part of the prep-
arations for the 2009 guidelines. Disappointingly, practices had
not improved in the 7 years since the previous survey. Against
the guidance of the BTS, 61% of respondent hospitals rec-
ommended b-lactam/macrolide combination therapy for mild
hospitalized pneumonia. Forty-nine percent reported cephalos-
porins as first-line antibiotic therapy for severe CAP, with only
34% recommending the BTS first-line therapy of co-amoxiclav
and macrolide. Only 38% of hospitals reported that local gui-
dance was influenced by concerns over C. difficile.100 A further
concerted effort is required to reduce inappropriate prescribing
and improve adherence to the guidelines. Figure 4 summarizes
management practices in RTIs that may have a role in reducing
CDI. There is little published evidence to suggest that manipulat-
ing CAP management can reduce CDI; however, in large part the
recommendations in Figure 4 represent best practice for CAP
patients, irrespective of the risk of CDI.
A summary of the evidence supporting the measures
discussed in this review is shown in Table 3.
Conclusions
The CDI epidemic has forced us to re-evaluate how we use anti-
microbials in hospitals and to examine management practices
for RTIs. There are clear areas for improvement in the manage-
ment of RTIs in the UK and elsewhere, improvements that may
lead to a reduction in CDI.
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